2022 La Revue de medecine interne

[Interest of Apremilast in idiopathic recurrent aphthous stomatitis: Review of two clinical cases].

, , , ,

La Revue de medecine interne Vol. 43 (5) : 312-315 • May 2022

INTRODUCTION: Apremilast is a phosphodiesterase 4 inhibitor used in psoriasis and psoriatic arthritis Recently, this treatment has received marketing authorization for severe and refractory oral aphthosis in Behcet's disease. Idiopathic recurrent aphthous stomatitis (RAS) outside of Behcet's disease is often difficult to treat and can affect patients' quality of life. CASE REPORTS: We report our experience with the use of apremilast in two 49-year-old patients with refractory oral aphthosis not related to Behcet's disease or another etiology. In both cases, a combination of apremilast with low-dose prednisone controlled the idiopathic RAS within a few weeks. CONCLUSION: Apremilast, which already has marketing authorization for Behcet's disease, also appears to be effective in RAS.

No clinical trial protocols linked to this paper

Clinical trials are automatically linked when NCT numbers are found in the paper's title or abstract.
PICO Elements

No PICO elements extracted yet. Click "Extract PICO" to analyze this paper.

Paper Details
MeSH Terms
Associated Data

No associated datasets or code repositories found for this paper.

Related Papers

Related paper suggestions will be available in future updates.